Home EIPG Newsletter

EIPG Newsletter

Looking for the solution against Covid-19

The search for a solution against Covid-19 sees researchers from all over the world looking for new drugs, remodulation of already approved medicines and development of a safe and efficient vaccine. But many are the still open questions wating for an answer from clinical research

How the EU Commission and the European medicines regulatory network are handling the Covid-19...

EMA, the EU Commission and the network of national competent authorities jointly acted to accelerate drug and vaccine development against Covid-19. A summary of the main actions

New M&A dynamics in an uncertain Covid-19 environment

The post-Covid opens many new opportunities in the filed of pharma M&A deals, expecially for larger pharmaceutical companies or spin-off creation, due to the global economic crisis consequent to the lockdown that might accelerate the transition of many no more sustainable businesses

Pharma workforce is moving forward post Covid-19

The Covid-19 has deeply redesigned the job market and the skills pharma worforce is expected to possess to face a still uncertain future. Analysis are available from consultancy firms on how CHROs should look at the new scenarios to sustain both business activities and the need for some employees to find a new position

EIPG: Consultations on Annex 21 and Annex 1, PharmSci podcast

EIPG aims to ensure that will influence the evolution of EU regulations and guidelines concerning standards of quality, safety, and efficacy of medicinal products. Important consultation calls seek the views of targeted interested parties on specific issues. Professor Gino Martini, Chief Scientist for the Royal Pharmaceutical Society in Great Britain talks about the latest issues, innovations and developments in the Pharmaceutical Sciences and research

Morocco: Drug Stock Management and Shortage Issues Related to Covid-19. Sharing the Moroccan Experience

The president of Moroccan Council of the Pharmaceutical Industry, Rachid Lamrini, tells about the country's experience in dealing with the Covid-19 emergency and reflects on its possible future impact on how to manage the global supply chain for pharmaceuticals

EIPG: Talks by Prof Martini, consultation on Annex 1 and Covid-19 related news

Professor Gino Martini, Chief Scientist for the Royal Pharmaceutical Society in Great Britain talks about the latest issues, innovations and developments in the Pharmaceutical Sciences and research. Piero Iamartino, Vice-President Technical and Professional Development, looks forward to hearing from you regarding the revised version of GMP Annex 1 consultation call. What are pharmaceutical companies doing in UK to tackle COVID-19

The EU’s new Industrial and Pharmaceutical Strategies

The Covid-19 epidemic has temporarily stopped the launch of the EU Commission's new Industrial and Pharmaceutical Strategies, initially due on March 11th. In the mean time, the industrial think tanks expressed their respective positions for the future of the European pharmaceutical industry

New guidances for gene therapy

The last couple of years saw the release by EMA of several new guidelines on different aspects of the development and use of gene therapies, including GCPs, exemption from batch controls, use of out-of-specification batches, and comparability studies

The impact of falsified medicines

EMA has warned the general public on the possible impact of falsified medicines during the Covid-19 emergency, while the OECD and EUIPO have published a report discussing the main features of the business of counterfeited drugs at the international level